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Nemaline myopathy (NM) is a genetic muscle disorder characterized by muscle dysfunction
and electron-dense protein accumulations (nemaline bodies) in myofibers. Pathogenic
mutations have been described in 9 genes to date, but the genetic basis remains unknown
in many cases. Here, using an approach that combined whole-exome sequencing (WES)
and Sanger sequencing, we identified homozygous or compound heterozygous variants in
LMOD3 in 21 patients from 14 families with severe, usually lethal, NM. LMOD3 encodes
leiomodin-3 (LMOD3), a 65-kDa protein expressed in skeletal and cardiac muscle. LMOD3
was expressed from early stages of muscle differentiation; localized to actin thin filaments,
with enrichment near the pointed ends; and had strong actin filament-nucleating activity.
Loss of LMOD3 in patient muscle resulted in shortening and disorganization of thin
filaments. Knockdown of lmod3 in zebrafish replicated NM-associated functional and
pathological phenotypes. Together, these findings indicate that mutations in the gene
encoding LMOD3 underlie congenital myopathy and demonstrate that LMOD3 is essential
for the organization of sarcomeric thin filaments in skeletal muscle.
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Introduction
Nemaline myopathy (NM) is a common form of congenital myopa-
thy, affecting approximately 1 in 50,000 individuals, and is defined 
by the presence of nonprogressive generalized muscle weakness 
and numerous electron-dense protein inclusions (nemaline bod-
ies or rods) in skeletal myofibers (1). The most severely affected 
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were nonsense or frameshift muta-
tions that are predicted to truncate 
LMOD3 (Figure 1 and Table 1). A 
heterozygous missense variant in 
LMOD3, c.976G>C (p.G326R), was 
identified in probands from 2 unre-
lated families (families 8 and 10) in 
association with different heterozy-
gous truncating mutations (Figure 1  
and Table 1). This variant was not 
present in the National Heart, Lung, 
and Blood Institute Exome Sequenc-
ing Project or the 1000 Genomes 
databases, which contain exome 
sequence data from a large number 
of individuals without muscle disor-
ders, suggesting that the c.976G>C 
variant is very rare in the general 
population and is very unlikely to be associated with severe NM in 
families 8 and 10 by chance alone. Amino acid G326 is conserved 
in the LMOD1, LMOD2, and LMOD3 and TMOD1, TMOD2, and 
TMOD3 proteins and is located within the leucine-rich repeat 
domain of LMOD3 (Figure 1), which is predicted to bind actin. In 
silico prediction of the functional consequences of this variant was 
supportive of pathogenicity (PolyPhen-2 score 1.00 = probably 
damaging, SIFT score 0 = damaging). Together, these data support 
the hypothesis that the c.976G>C (p.G326R) variant disrupts gene 
function and is pathogenic.
Although tissue was not available from affected individu-
als in all families, Western blotting confirmed that many muta-
tions result in no detectable LMOD3 protein in muscle, with the 
exception of patient 14a, in whom protein expression from both 
mutant alleles was demonstrated (Figure 2A and Table 1). To con-
firm these results, we analyzed primary myoblast cell lines and/or 
fibroblast cell lines (transformed into myogenic cells using MyoD 
transduction; refs. 4, 5) derived from the probands of families 12 
and 14. Western blot analysis confirmed the absence of LMOD3 
expression in myotubes from family 12 and the expression of both 
mutant forms of LMOD3 in myotubes from patient 14a (Figure 
2B). In addition, we confirmed that the polyclonal LMOD3 Ab we 
used was able to detect N-terminal protein fragments 51–amino 
acids long (Supplemental Figure 1), corresponding to the shortest 
predicted LMOD3 truncation in our cohort.
NM patients with LMOD3 mutations typically have severe con-
genital NM and distinctive nemaline body morphology on electron 
microscopy. NM patients with LMOD3 mutations (LMOD3-NM) 
presented with severe congenital NM in 90% of cases (13 of 14 
families) (Table 2). Antenatal manifestations included polyhy-
dramnios (62% of patients), decreased or absent fetal movements 
(48% of patients), and joint contractures (often multiple, 48% of 
patients). Thirty-five percent of patients were born prematurely. All 
patients had severe generalized hypotonia and weakness at birth, 
respiratory insufficiency, feeding difficulties, and bulbar weakness 
(Figure 3, A and B, and Table 2). Twenty-nine percent of patients 
had ophthalmoplegia, which is uncommon in other genetic forms 
of NM. Most patients died in the neonatal period from respiratory 
failure. No cardiac abnormalities were reported. Two sisters from 
children with NM die in the neonatal period from respiratory 
insufficiency. Less severely affected patients often have difficul-
ties walking and swallowing and require nocturnal respiratory 
support. Nine genes have been linked to NM to date; NEB, ACTA1, 
TPM3, TPM2, CFL2, and TNNT1 all encode components of the 
sarcomeric thin filament in skeletal muscle, while KBTBD13, 
KLHL40, and KLHL41, which belong to the BTB-BACK-kelch 
(BBK) protein family, are thought to be involved in ubiquitina-
tion and protein degradation (2, 3). However many patients with 
NM do not have identifiable mutations in these genes, suggesting 
there is further genetic heterogeneity.
Whole-exome sequencing (WES) and other approaches that 
use next-generation sequencing technology have revolution-
ized gene discovery by allowing rapid, cost-effective screening 
of large regions of the genome for potentially pathogenic vari-
ants. To identify further genetic causes of NM, we used WES on 
2 multiplex NM families who lacked a genetic diagnosis after 
standard investigations.
Results
Mutations in LMOD3 are a new genetic cause for NM and most muta-
tions result in complete loss of leiomodin-3 protein expression. WES in 2 
unrelated families with NM identified likely mutations in LMOD3, 
which encodes leiomodin-3 (LMOD3). In the consanguineous fam-
ily 1, a homozygous frameshift variant in LMOD3 was identified 
in both affected siblings. In nonconsanguineous family 14, WES 
identified previously unreported compound heterozygous LMOD3 
variants in both affected children. In both families, segregation was 
consistent with autosomal recessive inheritance.
Genetic screening of the 3 coding exons of LMOD3 by Sanger 
sequencing, WES, or whole-genome sequencing in over 540 addi-
tional genetically unresolved probands with NM identified likely 
pathogenic variants in 17 patients from 12 additional families (Fig-
ure 1 and Table 1). Segregation studies were consistent with auto-
somal recessive inheritance. Most other common genetic causes of 
NM had been excluded previously in patients in whom LMOD3 vari-
ants were identified (Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI75199DS1). 
LMOD3 variants were distributed throughout the gene and most 
Figure 1. LMOD3 mutations in patients with LMOD3-NM. Schematic of LMOD3 (NP_938012) showing domain 
organization, with mutation positions indicated. Protein structure information was obtained from Chereau 
et al. (10), UniProt (http://www.uniprot.org/), and InterProScan 4 (37). LMOD3 contains 3 actin-binding 
domains (red) (actin-binding helix [A-h], residues 69–79; leucine-rich repeat domain [LLR], residues 237–402; 
Wiskott-Aldrich-syndrome protein homology 2 domain [WH2], residues 534–553) and 1 TM-binding helix 
(TM-h, residues 29–40). The functions of the proline-rich region (PolyP, residues 449–457), Glu-rich region 
(residues 86–179), and basic region (B, residues 489–498) are unknown. Mutations indicated in red font are 
associated with expression of mutant protein in Western blot studies (see Figure 2).
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A zebrafish model of LMOD3-NM recapit-
ulates the human phenotype. As further confir-
mation that loss of LMOD3 leads to skeletal 
muscle disease, we developed a zebrafish 
knockdown model of LMOD3-NM (Figure 4). 
Coinjection of 2 morpholinos targeting dif-
ferent splice sites of the zebrafish lmod3 
gene achieved a knockdown of gene tran-
scripts and markedly reduced Lmod3 pro-
tein expression in injected zebrafish (Figure 
4B). lmod3 knockdown fish larvae (lmod3 
MO) assessed 3 days after fertilization had 
short bodies, bent tails, and reduced tail 
birefringence, consistent with abnormal 
skeletal muscle organization, which was 
also observed on EM images (Figure 4A and 
Supplemental Figure 3). lmod3 MO also had 
reduced trunk muscle cross-sectional areas 
(lmod3 MO: 0.021 ± 0.003 mm2 [n = 5], 
control morphants [control MO]: 0.028 
± 0.002 mm2 [n = 5], P = 0.003, 2-tailed 
unpaired t test). Immunostaining showed 
aberrant accumulations of the Z-disc protein 
α-actinin, a major component of nemaline 
bodies (Figure 4, C and D). Knockdown 
embryos also demonstrated abnormal motor 
function, with reduced spontaneous coiling 
(lmod3 MO: 0.7 ± 0.2 coils per 15 seconds 
[n = 68], control MO: 5.7 ± 0.5 coils per 
15 seconds [n = 76], P < 0.0001; Figure 
4E) and diminished touch-evoked escape 
responses (lmod3 MO: average 1.0 ± 0.1 
[n = 55], control MO: average 2.6 ± 0.1 
[n = 134], P < 0.0001; Figure 4F). Trunk 
muscles of lmod3 MO (3 days after fertiliza-
tion) generated less force (lmod3 MO: 4 ± 3 
mN/mm2 [n = 5], control MO: 26 ± 6 mN/
mm2 [n = 5], P < 0.0001; Figure 4G). Forces 
were normalized to cross-sectional area to confirm that weakness 
of lmod3 MO was not solely due to reduced lmod3 MO muscle size.
LMOD3 is expressed in skeletal muscle throughout life and local-
izes to the actin thin filament. The leiomodins are members of 
the tropomodulin protein family, and 3 leiomodin genes have 
been identified so far: LMOD1, LMOD2, and LMOD3. LMOD1 is 
expressed predominantly in smooth muscle, while LMOD2 and 
LMOD3 are mainly found in skeletal and cardiac muscle (6, 7). 
Until now, LMOD3 has been little studied, and its roles in skeletal 
and cardiac muscle have been unclear.
We performed protein studies in healthy muscle to character-
ize LMOD3 expression and localization. Western blot analysis on 
control human heart and skeletal muscle biopsies demonstrated 
that LMOD3 was expressed at higher levels in skeletal muscle than 
in cardiac muscle, while the situation was reversed for LMOD2 
(Figure 5C). Using control human myoblast cell lines and muscle 
biopsies, we showed that LMOD3 was expressed soon after the 
start of myoblast differentiation and in skeletal muscle throughout 
life from at least 14 weeks gestation (Figure 5, A and B).
family 14 are the only known surviving patients, currently aged 10 
and 4 years. Lower limb muscle MRI in patient 14a demonstrated 
widespread atrophy and fatty infiltration of thigh and lower leg 
muscles, with relative sparing of some muscles, including vastus 
lateralis, gracilis, semimembranosus, semitendinosus, and exten-
sor digitorum longus (Supplemental Figure 2).
Light microscopy images of skeletal muscle biopsies were 
available from 11 patients, and electron microscopy (EM) images 
were available from 6 patients. Histological assessment revealed 
nemaline bodies and atrophic myofibers in all LaMOD3-NM 
muscle biopsies. Interstitial connective tissue was increased in 
all biopsies and had almost completely replaced myofibers in 5 
of 11 biopsies (Figure 3D). On EM images, many nemaline bodies 
resembled short thickened Z-discs (seen in all 6 patients for whom 
EM images were available; Figure 3, G and H), often in doublets 
interconnected by filaments (present in 4 of 6 patient biopsies; 
Figure 3I). Some nemaline bodies were surrounded by a short thin 
filament “fringe” 60–220 nm in length (Figure 3, I and J; present 
in 3 of 6 patient biopsies).
Table 1. LMOD3 variants and protein expression 
Patient ID LMOD3 genotypeA Protein expressionB
1a hom c.138dupC, p.S47fs*13 p.S47fs*13 (6.6 kDa), no expression
1b hom c.138dupC, p.S47fs*13 p.S47fs*13 (6.6 kDa), N/D
2 hom c.138dupC, p.S47fs*13 p.S47fs*13 (6.6 kDa), N/D
3 hom c.154delA, p.M52* 3a and 3b - p.M52* (5.7 kDa), N/D
4 hom c.231G>A, p.W77* p.W77*(8.7 kDa), no expression
5 het c.300_304delGACTC, p.T101Rfs*4
het c.601_602delGA, p.D201Efs*9
p.T101Rfs*4 (12 kDa), no expression
p.D201Efs*9 (24 kDa), no expression
6 hom c.349C>T, p.Q117* p.Q117*(13.6 kDa), inconclusive
7 het c.349C>T, p.Q117*
het c.1218delA, p.K406Nfs*11
p.Q117* (13.6 kDa), inconclusive
p.K406Nfs*11 (48.2 kDa), inconclusive
8 het c.723_733del, p.D242Efs*4
het c.976G>C, p.G326R
p.G326R
p.D242Efs*4 (28.3 kDa), N/D
9 hom c.860delT, p.F287Sfs*3 p.F287Sfs*3 (33 kDa), no expression
10 het c.976G>C, p.G326R
het c.1372C>T, p.Q458*
p.Q458* (52.9 kDa), N/D
p.G326R
11a hom c.1069G>T, p.E357* p.E357* (41.1 kDa), N/D
11b hom c.1069G>T, p.E357* p.E357* (41.1 kDa), N/D
12aC hom c.1099_1100delAA, p.N367Qfs*11 p.N367Qfs*11 (43 kDa), no expression
12b hom c.1099_1100delAA, pN367Qfs*11 p.N367Qfs*11 (43 kDa), N/D
12c hom c.1099_1100delAA, p.N367Qfs*11 p.N367Qfs*11 (43 kDa), no expression
13a hom c.1099_1100delAA, p.N367Qfs*11 p.N367Qfs*11 (43 kDa), N/D
13b hom c.1099_1100delAA, p.N367Qfs*11 p.N367Qfs*11 (43 kDa), N/D
14a het c.1100_1102delACA, p.N367del
het c.1201C>T, p.R401*
p.R401* (48 kDa), expressed
p.N367del (64.8 kDa), expressed
14b het c.1100_1102delACA, p.N367del
het c.1201C>T, p.R401*
p.N367del, N/D
p.R401*, N/D
ANumbering of the nucleotide and protein changes is relative to NM_198271.3 (gene) and NP_938012 
(protein).BFull-length LMOD3 protein is 560–amino acids long and has a predicted molecular weight 
of 64.9 kDa. Molecular weight predictions were performed using ExPASy (http://web.expasy.org/
compute_pi/). The presence or absence of protein expression was assessed by Western blot analysis. 
CCorresponds to BOS-1120. Hom, homozygous; het, heterozygous; N/D, not determined (no muscle 
was available for analysis); inconclusive, biopsy contained only small amounts of muscle tissue, and 
the presence or absence of mutant LMOD3 expression could not be determined conclusively. 
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chain [MHC] analysis) or age was found (Supplemental Figure 6). 
We compared the breadth of LMOD3 staining across a full sar-
comere to the thin filament length, measured using phalloidin in 
the same sarcomere, and found that, while they closely correlated 
in fast fibres, the breadth was significantly shorter in slow fibers 
(P < 0.0001, paired t test). This suggests that LMOD3 binding may 
extend to the thin filament cap in fast fibers but ends before the 
cap in slow fibers (Figure 6, E and F). When the LMOD3 signal 
was enriched near the pointed end, the band appeared wider than 
those obtained for TMOD1 and TMOD4. At higher magnification, 
the wide LMOD3 band could occasionally be resolved into 2 nar-
row bands (Figure 6D and refs. 8, 9). The intense LMOD3 stained 
peak near the pointed end was further away from the Z-disc in fast 
myofibers(1.07 ± 0.1 3 μm, n = 14) compared with slow myofibers 
(0.91 ± 0.14 μm, n = 15, P = 0.0044, t test; Figure 6E). Notably, 
the peak of LMOD3 staining in both myofiber types was signifi-
cantly closer to the Z-disc than that of TMOD1 (average of fast and 
slow myofibers), which was located 1.26 ± 0.16 μm (n = 4) from the 
Z-disc, suggesting that LMOD3 may be located near, but not at, 
the thin filament pointed end.
Localization of LMOD3 within skeletal muscle sarcomeres 
was assessed by immunolabeling of stretched adult human con-
trol muscle and differentiated cultured control myotubes. LMOD3 
was highly expressed in nonstriated areas of developing myotubes 
and showed a granular cytoplasmic staining (Figure 5, D and E, 
square 2). In areas in which myosin and actin filaments were orga-
nized into sarcomeres, LMOD3 showed intense staining of the M 
band region, which colocalizes with thin filament pointed ends in 
unstretched sarcomeres. Less intense staining was observed along 
thin filaments, and the Z-discs were unstained (Figure 5, D and 
E, square 1). Expression of mCherry-labeled LMOD3 in cultured 
quail myotubes provides additional evidence for localization to the 
M line/thin filament pointed end region (Supplemental Figure 4).
In stretched mature human skeletal muscle, we observed 
3 staining patterns: (a) exclusive staining near the pointed end 
of thin filaments, (b) combined staining near the pointed end 
and along the thin filament, and (c) predominant staining along 
the thin filament (Supplemental Figure 5). In 4 of 5 biopsies, we 
observed more than one staining pattern in different myofibers, 
and no correlation with fiber type (determined by myosin heavy 
Figure 2. Most LMOD3 mutations abolish LMOD3 protein expression. Western blots assessing LMOD3 expression in available (A) patient muscle tissue 
and (B) patient primary muscle cells. (A) In most patients with nonsense or frame-shift mutations, truncated protein of the predicted size were not 
detected. In some biopsies, replacement of muscle tissue by connective tissue may limit our ability to detect a muscle-specific truncated product (e.g., 
lanes 4, 10, 13, and 14; expression of sarcomeric actin and α-actinin-2 is low relative to that of GAPDH). Muscle from patient 14a shows expression of 
truncated protein from both mutant LMOD3 alleles (red arrow, mutations in red in Figure 1). The approximately 50-kDa band (lanes 4, 10, and 14 and 
weakly in controls) does not correlate with the predicted molecular weight of mutant LMOD3 in these patients (12–43 kDa). This band likely arises from Ab 
cross-reactivity with a nonmuscle LMOD isoform or an unrelated nonmuscle antigen. (B) Primary myoblasts were differentiated into myotubes, and pri-
mary fibroblasts were MyoD-converted into differentiated myotubes in culture. Primary cells from controls express LMOD3 (~80-kDa band) and other thin 
filament markers (sarcomeric actin and α-actinin-2) after 5 days (d5) of differentiation (lanes 6 and 8). Myogenic conversion of fibroblasts from patient 
14a induces expression of mutant LMOD3 from both alleles (lane 10; R401*, red arrow). Primary myotubes and MyoD-converted fibroblasts from patient 
12c (homozygous p.N367Qfs*11) express no mutant protein (lanes 12, 13, and 15). These results replicate LMOD3 expression obtained in patient and control 
muscle biopsies. L, leg muscle; P, paraspinalis muscle; Q, quadriceps; T, triceps.
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indicating a higher TM binding affinity. Unfolding curves of TM/
LMOD peptide complexes indicated that the LMOD2 peptide 
binds approximately 4-fold more strongly to the α-TM N-termi-
nal peptide than the LMOD3 peptide (KD = 3.5 ± 0.5 μM for TM/
LMOD3 and 0.9 ± 0.3 μM for TM/LMOD2, n = 3; Figure 7B).
Thin filament structure is altered in patients with LMOD3-NM 
and lmod3 KO zebrafish. We assessed thin filament architecture in 
LMOD3-NM by dissecting longitudinal myofiber bundles from 9 
patient biopsies and staining stretched bundles with phalloidin, 
which labels filamentous actin (Figure 8, A–J). In half of the 
biopsies we found no discernible sarcomeric structure (patients 
4, 5, 6, and 9). In all other patient biopsies we observed varying 
degrees of thin filament shortening and disorganization (patients 
1a, 7, 12a, 14a; Supplemental Table 2). Four biopsies from three 
patients (patients 1a, 12a, and 14a) also contained regions with 
well-organized sarcomeres, and such regions were also seen on 
EM images (Figure 3, G and H).
LMOD3 is a potent actin nucleator and has a weaker binding affin-
ity to tropomyosin compared with that of LMOD2. Previous studies 
have shown that LMOD2 localizes to the pointed end of actin fil-
aments in cardiomyocytes and is a potent actin filament nucleator 
(10–12). We used a pyrene actin nucleation assay to compare the 
actin nucleation properties of LMOD2 and LMOD3 and observed 
that both leiomodins led to a marked increase in rate of actin poly-
merization, with an equivalent dose dependence (Figure 7A).
The leiomodins share a single tropomyosin (TM) binding 
domain with TMOD, and amino acid sequence analysis showed 
that LMOD3 is more divergent from TMOD1 than LMOD2 in this 
region (Figure 1 and Supplemental Figure 7, amino acids 29–40 in 
LMOD3). We performed far-UV circular dichroism (CD) spectral 
studies to test binding of an N-terminal α-TM peptide to LMOD2 
and LMOD3 peptides. CD spectral studies indicated complex 
formation for TM/LMOD2 and TM/LMOD3 peptide mixtures 
(Figure 7C). The increase in α-helicity was stronger for LMOD2, 
Table 2. Clinical features of LMOD3-NM 
Patient ID Genotype Ethnicity Sex Clinical  
subtypeA
Clinical features
1a p.S47fs*13 Algerian F SC Deceased (neonatal period)B. Polyhydramnios, preterm delivery (30/40), arthrogryposis, 
fractures (bilateral femoral).
1b p.S47fs*13 Algerian F SC Deceased (neonatal period). Preterm delivery (36/40).
2 p.S47fs*13 Belgian M SC Deceased (10 months). Decreased fetal movements, breech presentation, arthrogryposis, 
ophthalmoplegia.
3a p.M52* Portuguese F SC Deceased (neonatal period). Polyhydramnios, decreased fetal movements, contractures.
3b p.M52* Portuguese F SC Alive at 1 month, lost to follow-up. Polyhydramnios, contractures. 
4 p.W77* Japanese M SC Alive at 4 months, lost to follow-up.
5 p.T101Rfs*4 / p.D201Efs*9 Japanese F SC Alive at 2 months, lost to follow-up. Polyhydramnios, decreased fetal movements, subdural 
hematoma.
6 p.Q117* Japanese F SC Alive at 10 months, lost to follow-up. Polyhydramnios, decreased fetal movements, fetal edema, 
preterm delivery (32/40), microcephaly, contractures.
7 p.Q117* / p.K406Nfs*11 Japanese F SC Alive at 1 year 7 months, lost to follow-up. Polyhydramnios, decreased fetal movements, 
ophthalmoplegia.
8 p.D242Efs*4 / p.G326R South American F SC Deceased (neonatal period).
9 p.F287Sfs*3 Italian F SC Deceased (4 months). Polyhydramnios, decreased fetal movements, preterm delivery (34/40), 
ophthalmoplegia, contractures.
10 p.G326R / p.Q458* Ecuadorian M SC Deceased (6 weeks). Polyhydramnios, decreased fetal movements, preterm delivery (35/40), 
breech presentation, ophthalmoplegia, arthrogryposis, fractures (bilateral humeral).
11a p.E357* Swedish M SC Deceased (5 months). Polyhydramnios, arthrogryposis.
11b p.E357* Swedish M SC Deceased (neonatal period).
12aC p.N367Qfs*11 Afghani M SC Deceased (2 months). Absent fetal movements, preterm delivery (31/40), breech presentation, 
arthrogryposis.
12b p.N367Qfs*11 Afghani M SC Deceased (neonatal period). Preterm delivery (33/40), arthrogryposis.
12c p.N367Qfs*11 Afghani Affected fetus.
13a p.N367Qfs*11 Pakistani F SC Deceased (3 months). Polyhydramnios, breech presentation, ophthalmoplegia, kyphosis.
13b p.N367Qfs*11 Pakistani F SC Deceased (neonatal period). Polyhydramnios, decreased fetal movements.
14a p.N367del / p.R401* Australian F TC Alive (10 years). Polyhydramnios, decreased fetal movements, bulbar weakness, 
ophthalmoplegia, percutaneous endoscopic gastrostomy, nocturnal noninvasive ventilation. 
Walks independently. Normal cardiac assessment and echocardiogram.
14b p.N367del / p.R401* Australian F TC Alive (4 years). Polyhydramnios, bulbar weakness, percutaneous endoscopic gastrostomy, 
nocturnal noninvasive ventilation. Walks with truncal support. Normal cardiac assessment and 
echocardiogram.
AClassification of clinical subtype of NM relates to the European Neuromuscular Centre classification of NM (1). BNeonatal period indicates less than  
28 days of age. CCorresponds to BOS-1120. TC, typical congenital NM; SC, severe congenital NM; F, female; M, male; 30/40, gestational age of 30 weeks.
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Ultrastructural analysis of skeletal muscles from lmod3 MO 
zebrafish also showed regions with ordered sarcomeres when 
LMOD3 was knocked down. Electron micrographs of zebrafish 
skeletal muscle showed subtle differences in appearance around 
the M line in lmod3 MO zebrafish compared with controls (Supple-
mental Figure 3, A and B). This could represent either loss of the 
border of the H zone, which relies on well-aligned thin filament 
pointed ends (see Supplemental Figure 3C) or, alternatively, could 
be due to abnormal organization of myosin thick filaments.
To further investigate whether dysregulation of thin filament 
length contributes to muscle weakness in LMOD3-NM, we isolated 
myofiber bundles from LMOD3-NM patient and control muscle 
biopsies and measured the force to sarcomere length (SL) relation-
ship. In normal muscle, actin filament length is tightly controlled 
to ensure optimal thin-thick filament overlap for efficient force 
generation at optimal muscle stretch. At SLs greater than approx-
imately 2.6 μm, the overlap of the contractile filaments decreases, 
resulting in a linear decrease of force production (descending 
limb). Assuming a constant thick filament length, the shape of the 
force/SL curve is determined by the length of the thin filament (13). 
We were able to perform force 
measurements at SLs of 2.0 to 
3.5 μm in the 3 biopsies from 
patients 14a and 12a, the biop-
sies with the best sarcomeric 
organization (Figure 8, K–M). 
Highly variable contractile 
force (patient 1a) or no mea-
surable force (patients 4 and 
7) was obtained in other biop-
sies, likely because muscle 
structure was too disordered. 
Interestingly, maximal force 
normalized to cross-sectional 
area in both biopsies from 
patient 14a was the same as 
that in controls (mean force: 
62.06 ± 15.82 and 61.25 ± 19.56 
mN/mm2 in patient myofibers 
and 61.94 ± 22.07 mN/mm2 
in 5 controls), while patient 
12a myofibers produced 57% 
less force than controls (26.72 
± 6.34 mN/mm2; P < 0.0001) 
(Figure 8K). In all 3 biopsies, 
there was a leftward shift in 
the force/SL curve, consistent 
with decreased thin filament 
lengths in these patients (Fig-
ure 8L). Patient 12a produced 
less specific force at all SLs.
Several thin filament pointed 
end proteins are dysregulated in 
LMOD3-NM. We investigated 
the expression of LMOD2, 
another striated muscle leio-
modin, and the 2 sarcomeric 
skeletal muscle tropomodulins, TMOD1 and TMOD4, in available 
patient muscle biopsies using Western blot analysis. We found 
increased LMOD2 expression in all patients tested, compared with 
age-matched control biopsies. TMOD1 expression was variable in 
both groups, and TMOD4 expression was uniformly decreased in 
patient biopsies (Figure 9). TMOD1 and TMOD4 immunostain-
ing on stretched patient bundles showed that both proteins still 
localized to the pointed end of thin filaments in myofibrils with 
discernible sarcomeric structure (Supplemental Figures 8 and 9). 
However, in the fiber bundles extracted from muscle from patient 
12a, TMOD1 labeling was enriched in some areas containing pro-
tein accumulations (Supplemental Figure 8). LMOD2 and LMOD3 
staining was not consistently detected in stretched bundles from 
either controls or patients, suggesting that the process of preparing 
stretched myofiber bundles from frozen biopsies disrupts staining 
with these Abs, unfortunately.
Discussion
We describe 21 patients from 14 families who have compound het-
erozygous or homozygous mutations in LMOD3 consistent with 
Figure 3. Clinical and histological features in NM due to LMOD3 mutations. (A and B) Photographs of patients with 
LMOD3-NM. (A) Most affected individuals had severe generalized muscle weakness and hypotonia at birth and died 
in infancy (patient 9, severe congenital NM). (B) Patient 14a has less severe weakness and has survived into child-
hood. Note the severe facial and jaw weakness. (C) Control Gomori trichrome image (5-month-old child).  
(D and E) Skeletal muscle biopsy findings in (D) patient 6 and (E) patient 4. (D) Some biopsies had only a few scat-
tered atrophic myofibers within abundant connective tissue. Nemaline bodies appear as purple or blue inclusions 
(arrow). (F) Control EM image (6-week-old child, rectus abdominis muscle). (G and H) EM images from some patient 
biopsies show myofibers with ordered sarcomeres adjacent to myofibers with disordered sarcomeres and thickened 
Z-discs. (I and J) Many nemaline bodies appear as thickened Z-discs, (I) sometimes in pairs interconnected by thin 
filaments. Some nemaline bodies resemble thickened Z-discs surrounded by a short thin filament “fringe.” Images 
show (G and J) patient 12a, (H) patient 14a, and (I) patient 1a. Scale bar: 50 μm (C–E); 2 μm (F–H); 500 nm (I and J).
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autosomal recessive inheritance, associated with severe NM, estab-
lishing LMOD3 as a new cause of this disorder. As further confirma-
tion, we developed a zebrafish model of LMOD3-NM and demon-
strated abnormalities in skeletal muscle organization and function 
after LMOD3 knockdown.
The clinical presentation of LMOD3-NM is characterized by 
early-onset severe generalized muscle weakness and hypotonia, 
with respiratory insufficiency and feeding difficulties. The severe 
congenital subtype of NM is relatively uncommon, accounting for 
only 16% of patients with NM in a large case series (14). Ninety per-
cent of patients with LMOD3-NM identified in the current study 
had severe congenital NM, establishing LMOD3 as an important 
cause of this phenotype, in addition to ACTA1, NEB, KLHL40, and 
KLHL41. Features commonly seen in LMOD3-NM, which may 
serve as clinical clues for the disorder, include arthrogryposis or 
congenital contractures, ophthalmoplegia, and a history of pre-
maturity, reduced fetal movements, and polyhydramnios. We also 
report a distinctive ultrastructural appearance of nemaline bodies 
in LMOD3-NM. Many of the nemaline bodies resembled thick-
ened Z-disc remnants, which often appeared in pairs, surrounded 
Figure 4. Morpholino knockdown of lmod3 in zebrafish recapitulates features of LMOD3-NM. (A) Representative bright-field (top) and birefringence 
(bottom) images of control and lmod3 knockdown zebrafish morphants 3 days after fertilization (dpf). Note the shorter body size, bent tail, and reduced 
birefringence of lmod3 MO. (B) RT-PCR from embryos injected with control morpholinos (lanes 2, 3, 6, and 7) or lmod3 morpholinos (lanes 4 and 8). 
Knockdown of the lmod3 gene was achieved using 2 morpholinos directed against different splice sites. PCR, performed with primers targeting lmod3 
spanning exons 1–3 (lanes 2–4) and exons 2–4 (lanes 6–8), demonstrates successful interruption of splicing by the lmod3 morpholinos. LMOD3 protein 
expression was markedly reduced in lmod3 MO embryos by (B) Western blotting and (C) immunohistochemistry. (D) Isolated myofibers from lmod3 MO 
immunostained with α-actinin show protein accumulations resembling nemaline bodies (white arrows). No accumulations were observed in control MO 
(data not shown). (E) Spontaneous embryo coiling 24 hours after fertilization (hpf) was significantly reduced in lmod3 MO. (F) A significant reduction in 
touch-evoked escape response (0–3 response scale) was observed 48 hours after fertilization in lmod3 MO. (G) Contractile force generated by lmod3 MO 
trunk muscle (3 days after fertilization) was significantly reduced. All error bars represent mean ± SEM. Scale bar: 5 μm (C and D). ****P < 0.0001, 2-tailed 
paired t test. CSA, cross-sectional area.
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and p.R401* mutant LMOD3 alleles in skeletal muscle. Patients 
14a and 14b are the only 2 patients known to have survived beyond 
early childhood, which suggests that one of these mutant proteins 
(or both) retains some function, conferring a milder phenotype. 
The fact that loss of LMOD3 leads to severe muscle dysfunction 
indicates that LMOD3 plays an essential role in skeletal muscle, 
which has not been recognized previously.
A striking feature in muscles from many patients with LMOD3-
NM is replacement of myofibers with connective tissue. After 
staining of actin filaments in individual myofibers with phalloidin, 
no discernible sarcomeres were seen in half of the patient muscle 
biopsies, indicating widespread disorganization of muscle ultra-
by highly shortened thin filaments. This appearance is rare in 
other forms of NM and may assist in diagnosing this condition. 
Interestingly, even though we demonstrated that LMOD3 is pres-
ent in cardiac muscle, cardiac involvement has not been reported 
so far in LMOD3-NM, and it is possible that LMOD2 may compen-
sate for loss of LMOD3 in cardiac muscle.
Most LMOD3 mutations we identified are nonsense or 
frameshift mutations that would truncate the LMOD3 protein 
if expressed. In almost all patients with LMOD3-NM for whom 
muscle biopsies were available, mutations in LMOD3 were asso-
ciated with a loss of LMOD3 expression. The only exception was 
family 14, in which we found expression of both the p.N367del 
Figure 5. LMOD3 expression in human muscle tissue and primary cells. LMOD3 expression during muscle cell differentiation and muscle development 
in (A) human skeletal muscle tissue and (B) differentiating primary human myoblasts. (A) In skeletal muscle, LMOD3 was detected at all ages tested 
(assessed age range: 14 weeks gestation to 58 years), but expression before birth was lower than that in mature muscle. Developmental MHC (dMHC) and 
cardiac actin (c actin) were expressed in fetal muscle biopsies as expected. Sarcomeric actin (s actin), α-actinin-2, GAPDH, and MHC (Coomassie-stained 
MHC [cMHC]) served as loading controls. (B) LMOD3 was detected weakly in undifferentiated human myoblasts (day 0 [d0]), and levels increased during 
differentiation into myotubes similar to other muscle proteins, such as α-actinin-2, developmental MHC, and cardiac actin. β-Tubulin served as a loading 
control. PHM Diff, primary human myoblasts differentiation. (C) LMOD2 and LMOD3 expression in mature human cardiac muscle and skeletal muscle. 
LMOD3 expression was higher in skeletal muscle than in heart, while the reverse was true for LMOD2. (D) Localization of LMOD3 in primary human myo-
blasts at day 10 of differentiation by confocal imaging. (E) Magnified view of white squares in D. Square 1 (S1) shows a striated area, demonstrating that 
LMOD3 was most abundant at the thin filament pointed end and/or M line, which colocalize in unstretched sarcomeres, and was absent from the Z-disc 
(yellow arrows). In square 2 (S2), LMOD3 staining appears granular in areas where striations have not formed. Scale bar: 7.5 μm (D and E). C, human heart; 
S, postnatal human skeletal muscle.
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Neb knockout mice, variability in thin filament lengths leads to loss 
of a clear boundary for the H zone (15). To obtain further informa-
tion about whether variable thin filament lengths may be a com-
mon finding in LMOD3-NM, we analyzed the force/SL relation-
ship in myofibers dissected from patient biopsies. The leftward 
shift in the force/SL curves in all biopsies tested confirms that, 
even in myofibers with well-ordered sarcomeres, populations of 
shortened thin filaments are present and likely contribute to mus-
cle weakness, a mechanism of disease previously linked to other 
forms of NM (16). Dysregulation of the tropomodulins, particu-
larly TMOD4, in skeletal muscle, may also contribute to muscle 
weakness in LMOD3-NM.
structure. A paucity of contractile units is likely the main cause of 
muscle weakness in most patients. When sarcomeres were pres-
ent, a range of structural abnormalities were seen, ranging from 
thickened Z-disc–like structures without thin filaments, to Z-discs 
with shortened thin filaments, to sarcomeres with near-normal 
structure. In addition, lmod3 MO zebrafish lacked clearly defined 
pale zones immediately adjacent to M lines. This appearance 
could be caused by abnormal myosin filament/M line structure or 
due to loss of distinct H bands, a finding reported in Neb knockout 
mice (15). The H zone represents the region of the sarcomere that 
only contains thick filaments, with the H zone boundary created 
by the well-aligned thin filament pointed ends at either side. In 
Figure 6. LMOD3 localizes to actin thin filaments in the muscle sarcomere. (A) TMOD1 pointed end localization and (B and C) 2 examples of LMOD3 
localization in stretched human control quadriceps muscles. Actin filaments were colabeled with Alexa Fluor 488–conjugated phalloidin (blue), α-actinin 
(Z-discs, red), and LMOD3 (green). (D) At higher magnification, LMOD3 pointed end staining can occasionally be resolved into 2 distinct bands. (E) Mea-
surements of LMOD3 and phalloidin signal breadth taken at the half peak height (LLMOD and LPhal, respectively), using methods illustrated in F. LLMOD and 
LPhal are indistinguishable in fast fibers (NS, paired t test), but LLMOD is shorter than LPhal in slow fibers (***P < 0.0001, paired t test), suggesting that LMOD3 
binding ends before the pointed end cap in slow fibers. (G) Measurements of the distance between the LMOD3 peak located near the pointed end and the 
Z-disc (fast and slow fibres) and the distance between the TMOD1 peak and the Z-disc (p-p, peak-to-peak), as illustrated in H. Thin filament lengths were 
measured in the same sarcomeres from phalloidin staining, as illustrated in F. The peak of the LMOD3 signal was significantly closer to the Z-disc in slow 
myofibers (***P = 0.0009, 2-tailed unpaired t test) and fast myofibers (*P = 0.0472, 2-tailed unpaired t test) as compared with TMOD1. The peak of LMOD3 
staining localized closer to the Z-disc in slow muscle myofibers compared with fast myofibers (**P = 0.0043, 2-tailed unpaired t test). (I) Diagram showing 
the hypothesized positions of LMOD3 pointed end binding relative to other thin filament proteins. Scale bar: 7.5 μm. Graphs show mean ± SD.
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pointed ends of thin filaments, a key site for actin turnover and 
control of thin filament length in skeletal muscle. We also demon-
strated that LMOD3, like LMOD2, is an effective catalyst of actin 
nucleation. In addition, loss or dysfunction of LMOD3, which 
defines LMOD3-NM, was associated with short thin filaments in 
immunofluorescent and force/SL measurement studies in patient 
myofibers. These data are all consistent with a central role for 
LMOD3 in modulating thin filament length in skeletal muscle.
In LMOD3-NM patient muscle, we observed an upregulation 
of LMOD2, another striated muscle leiomodin that is expressed 
at higher levels in cardiac muscle compared with skeletal mus-
cle. This may represent a specific upregulation of a homologous 
protein as a compensatory mechanism, a process that is well 
described to occur in patients with autosomal recessive mutations 
in ACTA1, which encodes α-skeletal actin, in whom cardiac actin is 
markedly upregulated in skeletal muscles after birth (17, 18). How-
ever, the presence of such severe muscle weakness in patients with 
LMOD3-NM suggests that the LMOD2 upregulation that occurs 
compensates poorly for the loss of functional LMOD3. The fact 
The N-termini of LMOD1, LMOD2, and LMOD3 have approx-
imately 40% sequence identity with the TMODs, sharing 2 act-
in-binding domains and 1 of 2 TM-binding sites (10). In addition, 
the C-termini of the leiomodins contain a third actin-binding 
domain, which is not present in the TMODs but which is a char-
acteristic of actin filament-nucleating proteins (Figure 1 and ref. 
10). Previous studies have shown that LMOD2 localizes near the 
pointed end of thin filaments in cardiomyocytes and functions as a 
potent actin filament nucleator in vitro (10–12).
To investigate the biological functions of LMOD3, we per-
formed a range of studies in control muscle samples and using 
recombinant protein. Tsukada et al. showed that LMOD2 regu-
lates thin filament lengths in cardiomyocytes likely by competing 
with TMOD, which caps actin filaments, and by promoting actin 
polymer extension at the pointed end of thin filaments (12). We 
hypothesized that LMOD3 may play a similar role in skeletal mus-
cle. Our studies using recombinant proteins and stretched quad-
riceps muscle show that, like all other members of the TMOD 
family, LMOD3 binds both actin and TM and localizes close to the 
Figure 7. Actin nucleation activity and TM binding of LMOD2 and LMOD3. (A) Nucleation/polymerization time course of 1.1 μM G-actin (10% pyrenyl- 
actin) after addition of polymerization buffer containing different concentrations of LMOD2 or LMOD3. LMOD2 and LMOD3 increase actin polymeriza-
tion/nucleation to a similar extent, compared with spontaneous actin nucleation/polymerization. (B) Binding of LMOD2 and LMOD3 peptides to TM 
peptides measured using CD spectroscopy. The graph shows the unfolding curves for individual peptides (e.g., TM, LMOD2, LMOD3), their mixture (TM/
LMOD2, TM/LMOD3), and the sum of individual unfolding curves (TM+LMOD2, TM+LMOD3). The dissociation constants (KD) of the peptide complexes 
were 3.5 ± 0.5 μM (n = 3) for TM/LMOD3 and 0.9 ± 0.3 μM (n = 3) for TM/LMOD2 (binding of LMOD3 to skeletal muscle TM is ~4 times weaker than that 
of LMOD2, P = 0.0018, 2-tailed t test). (C) Far-UV CD spectra for synthetic peptides corresponding to the TM-binding sites of LMOD3 and LMOD2 and 
the model TM peptide, TM1aZip, their mixtures, and the sums of the individual spectra (10 μM each, measured in 1-mm cuvettes at 10oC in 10 mM Na-
Phosphate buffer, pH 7.0, 100 mM NaCl). Based on shapes of the spectra for LMOD2 and LMOD3 peptides, α-helix/random coil ratio is lower for LMOD3 
peptide, suggesting it is less structured. The difference between the spectra of the TM/LMOD mixtures and the sums of corresponding individual spectra 
(TM+LMOD) demonstrates the increase in helicity and therefore indicates complex formation. The effect is stronger for LMOD2.
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may have several functions; it may bind near the pointed end of 
thin filaments to modulate filament length and also bind along the 
length of the thin filament to perhaps function as a thin filament 
stabilizer. Further studies are required to confirm this hypothesis.
In a recently published study, LMOD3 and nebulin were 
identified as major binding partners of KLHL40, loss of which 
results in a severe lethal form of NM associated with destabili-
zation of thin filament proteins (19, 20). KLHL40 was found to 
promote stability of LMOD3 by blocking its ubiquitination, and 
loss of KLHL40 was associated with almost complete absence 
of LMOD3 protein in skeletal muscles of mice and KLHL40- 
deficient patients. These data support a pivotal role for LMOD3 in 
the stability of the sarcomere thin filament. The newly identified 
interaction among LMOD3, nebulin, and KLHL40 provides the 
“missing link” between thin filament proteins and the kelch (BBK) 
protein family and suggests a common pathway for the pathogen-
esis of a number of different genetic forms of NM.
In conclusion, we show that autosomal recessive mutations 
in LMOD3 are a new and important cause of severe congenital 
NM and that LMOD3 plays a critical role in skeletal muscle biol-
ogy. Multiple lines of evidence point to a role for LMOD3 as a key 
regulator of thin filament length in skeletal muscle. This study 
emphasizes the power of WES in identifying the genetic basis of 
that LMOD2 and LMOD3 have different TM-binding affinities and 
the fact that LMOD2 does not compensate for the loss of LMOD3 
in LMOD3-NM suggest that, even though many properties are 
similar, there may be important differences in biological function 
between these proteins.
In stretched mature control muscle, LMOD3 staining was 
enriched in a wide band close to the pointed end of thin filaments. 
The distance of the staining peak from the Z-disc was different in 
slow and fast myofibers, raising the possibility that LMOD3 has dif-
ferent roles in the 2 myofiber types. LMOD3 staining differed from 
TMOD1 staining in several ways. LMOD3 staining near the pointed 
end was broader than for TMOD1 and the peak was closer to the 
Z-disc. These differences suggest that LMOD3 may not simply 
act as a competitive binding partner with TMOD1 for the pointed 
end, as has been proposed for LMOD2 (12). In addition, in approxi-
mately 50% of myofibers, staining was not restricted to the pointed 
end but was also present along thin filaments. Fiber type and 
biopsy age were not responsible for this variability, and the factors 
that determine the position of LMOD3 binding in different myofi-
bers have yet to be identified. Studies of LMOD2 have also found 
evidence of a variable localization, and, in the case of LMOD2, 
localization appeared responsive to muscle contraction (11). The 
evidence we present for variable localization suggests that LMOD3 
Figure 8. Patient myofibers show evidence of shortened/disorganized thin filaments. (A–J) Phalloidin-stained stretched myofiber bundles dissected 
from human LMOD3-NM patient biopsies. Thin filaments are well aligned and have consistent lengths in (A) controls and (I and J) some areas of patient 
muscle. (B–H) Representative images of patient muscles demonstrate moderate/severe sarcomere disorganization (asterisks), (C, D, and H) Z-discs with 
short protruding thin filaments, and (E and F) thickened Z-discs. Images show (A) control, (B and J) patient 14aQ, (C) patient 1a, (D and E) patient 7,  
(F and G) patient 14aT, and (H and I) patient 12a. (K) Maximal specific force (force/cross-sectional area) measurements at optimal SL (patient 12a: 2.2 μm; 
patient 14a and controls: 2.5 μm) in permeabilized myofiber bundles was normal in patient 14a compared with controls (n = 5), while patient 12a generated 
significantly less force (****P < 0.0001, 2-tailed t test). Force/SL curves (L) normalized to maximal force or (M) absolute force showed a leftward shift 
consistent with reduced force at longer SL in patients (patient 12a SL > 2.8, P < 0.001; patient 14aQ SL = 2.8, 3.2, and 3.5, P < 0.01, P < 0.001, and P < 0.05, 
respectively; patient 14aT SL > 3.2, P < 0.05; 2-way ANOVA). Error bars represent SEM. Scale bar: 10 μm.
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This reduced the candidate regions to 3% of the genome. WES was 
then performed in the index case. WES was performed in a similar 
manner to that described for family 14. Exome libraries were cap-
tured using the Agilent SureSelect V3. SNPs and small indels were 
called using SAM tools and annotated using ANNOVAR. Homozygous 
single nucleotide variants mapping to candidate loci were filtered as 
described for family 14.
Genetic screening for additional LMOD3 mutations
Bidirectional Sanger sequencing of LMOD3 was performed on bio-
banked DNA in 476 additional genetically unresolved patients with 
NM in Helsinki, London, Perth, Sydney, and Tokyo. LMOD3 was PCR 
amplified from genomic DNA in 4 fragments covering 3 exons using 
standard methods (PCR primer sequences in Supplemental Table 3). 
An additional 68 cases were screened by WES or whole-genome 
sequencing in Boston through the Boston Children’s Hospital Gene 
Partnership Program. WES in these cases was performed as previ-
ously described (3). In cases screened by whole-genome sequencing, 
rare genetic disorders, delivering accurate genetic counselling for 
families, permitting prenatal diagnosis, and facilitating studies of 
disease pathogenesis and treatment.
Methods
Gene identification and genetic screening
WES was performed in 2 siblings with NM and their unaffected non-
consanguineous parents (family 14 in Table 1), as described previously 
(21). Exome variant filtering for Mendelian disease gene discovery 
focused on genes containing homozygous or compound heterozygous 
variants (21). The Broad Institute whole-exome data set can be found 
in the database of Genotypes and Phenotypes site (http://www.ncbi.
nlm.nih.gov/gap; accession no. phs000655.v1.p1.). For more details, 
see the Supplemental Methods.
In family 1, candidate chromosomal loci were first identified by 
genetic mapping using Affymetrix 250K GeneChip microarrays and 
multipoint linkage analysis combined with homozygosity mapping. 
Figure 9. Levels of LMOD2 and TMOD4 are altered in LMOD3-NM. (A) Western blot analysis of thin filament pointed end proteins LMOD2, TMOD1, and 
TMOD4 in patients with LMOD3-NM and age-matched controls. Coomassie-stained MHC, sarcomeric actin, GAPDH, and α-actinin-2 served as loading con-
trols. (B) Histograms show normalized protein levels for TMOD1, TMOD4, and LMOD2 in patients with LMOD3-NM and controls. TMOD1 expression levels 
are variable in both patients and controls, with no consistent difference between these groups. TMOD4 levels are consistently reduced in patients with 
LMOD3-NM compared with age-matched controls. LMOD2 expression is upregulated in patients. Densitometry was performed using ImageJ, and values 
were normalized to α-actinin-2 levels and are scaled to mean control level = 1.0. Patients with low or no expression of muscle proteins were excluded from 
analysis (e.g., patient 4). Dotted lines show the average results for patients and controls, respectively.
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Mini Protease inhibitor (Roche) and a Dounce tissue homogenizer 
(Pierce Biotechnology). Approximately 60 μg protein was loaded per 
sample, resolved by polyacrylamide gel electrophoresis on 10% gels, 
and transferred to polyvinylidene fluoride membrane. After block-
ing in PBS containing 0.1% Tween, 5% dried milk, and 3% BSA, the 
membrane was probed with LMOD3 Ab (1: 5,000, Proteintech) and 
TMOD1 and TMOD4 (1:1,000, see Abs), with an actin Ab (1:10,000, 
Sigma-Aldrich) as loading control. Secondary Abs were used at 
1:5,000 (Bio-Rad), and blots were developed using electrochemi-
luminescence reagent (GE Biosciences).
Immunohistochemistry to determine LMOD3 localization  
in control muscle samples
Control quadriceps muscle tissue from 5 healthy individuals was fixed 
in 3% paraformaldehyde in a stretched position, embedded in Tis-
sueTek, and frozen in 2-methylbutane cooled in liquid nitrogen. Lon-
gitudinal 8-μm-thick cryosections were collected on glass slides and 
blocked for 1 hour in 4% BSA prepared in PBS, followed by incubation 
in primary Abs diluted in blocking solution for 2 hours at room temper-
ature. Sections were labeled with rabbit LMOD3 Ab and slow MHC, 
fast MHC, or α-actinin-2 Ab. Unbound Abs were removed by washing 
4 times in PBS, followed by 15 minutes of blocking as above. Second-
ary anti-mouse Alexa Fluor 647, anti-rabbit Alexa Fluor 488, and Alexa 
Fluor 488–conjugated phalloidin (diluted 1:20, Life technology) were 
incubated on muscle sections for 1 hour. Finally, slides were washed 
as above and mounted using Immu-Mount (Thermo Scientific). Stain-
ing was imaged by confocal microscopy. Five areas were imaged per 
control biopsy, ensuring sarcomeres were adequately stretched, as 
determined by phalloidin staining. In each area imaged, the staining 
pattern was recorded (pointed end staining, staining along the thin fil-
ament, and combined pointed end and thin filament staining) and the 
fiber type was determined with MHC staining.
A subset of images showing high-quality pointed end LMOD3 
staining were used to measure the distance from the Z-disc of the 
LMOD3 peak of intense staining. Measurements were first performed 
manually using ImageJ (profile blot function). Measurements were 
confirmed using Distributed Deconvolution Analysis (24).
Tissue culture
Primary patient and control fibroblast cultures were transduced with a 
MyoD-lentiviral vector to induce myogenic conversion as described pre-
viously (4). Primary patient and control myoblasts and MyoD-converted 
fibroblasts were grown to confluency and differentiated in 5% horse 
serum with 1x ITS for 5 to 8 days to induce myotube formation. Western 
blot was performed using 5 μg cell lysate from differentiated cells.
lmod3 MO zebrafish
Knockdown of lmod3 gene expression in zebrafish was achieved by 
coinjection of morpholinos directed against the splice acceptor site of 
exon 2 and the splice donor site of exon 3. Morpholinos were injected 
at a concentration of 0.3 mM. Morpholino experiments were con-
trolled by injecting an identical concentration and amount of standard 
control morpholino (GeneTools Inc.). All injections were done into 
1-cell stage AB zebrafish embryos. All embryos were manually decho-
rionated at day 1 after fertilization. Histopathology, including immun-
ofluorescence analysis of isolated myofibers and EM of muscle from 
whole embryos, was performed as previously described (25, 26).
this was performed by Complete Genomics and processed through 
their Standard Pipeline v. 2.2.
Abs
A polyclonal rabbit anti-LMOD3 Ab was purchased from Proteintech 
(14948-1-AP) and used at a dilution of 1:10,000 for Western blot and 
1:350 for immunohistochemistry. Two polyclonal rabbit LMOD2 Abs 
(Abcam, 108022, and Santa Cruz, sc-135493, S-12) were used for West-
ern blot at dilutions of 1:250 and 1:500, respectively. The specificity of 
LMOD2 and LMOD3 Abs was confirmed using recombinant proteins 
expressed in bacteria and COS cells (see Supplemental Figure 1). The 
rabbit α-actinin-2 Ab (clone 4A3, 1:250,000 for Western blot) was 
developed in-house by A.H. Beggs. Mouse α-actinin Ab was purchased 
from Sigma-Aldrich (EA-53, 1:400 immunohistochemistry). Total sar-
comeric actin levels were assessed using a mouse sarcomeric actin Ab 
from Sigma-Aldrich (5C5, 1:10,000 for Western blot). The GAPDH Ab 
was obtained from Millipore (MAB374, 1:10,000 for Western blot). 
Developmental MHC Ab, which recognizes the embryonic MHC iso-
form, was purchased from Novocastra Laboratories LTd (NCL-MHCd, 
dilution 1:200 for Western blot), cardiac actin Ab was purchased from 
American Research Product Inc. (1:1,500 for Western blot), slow MHC 
Ab was purchased from Chemicon International Inc. (MAB1628, dilu-
tion 1:3,000 Western blot, 1:1,000 immunohistochemistry), and fast 
MHC Ab was purchased from Sigma-Aldrich (MY-32, 1:800 immuno-
histochemistry). TMOD1 and TMOD4 Abs were produced in-house 
by V.M. Fowler (dilution for immunohistochemistry was 1:50 and 
1:100 for TMOD4 and TMOD1, respectively; ref. 22). Secondary Abs 
(Alexa Fluor 555 rabbit and Alexa Fluor 647 mouse, 1:200) for immu-
nohistochemistry were obtained from Molecular Probes, Invitrogen. 
HRP-conjugated secondary Abs for Western blot were purchased from 
GE Healthcare (1:2,000).
Western blot
Western blotting methods for human samples and cells were based 
on methods previously described with modifications (23). Protein 
concentration was determined via bicinchoninic acid BCA assay per 
manufacturer’s instructions (Pierce, Thermo Fisher Scientific). Five 
μg total muscle protein was separated on precast 10% SDS-PAGE gels 
(NuPAGE NovexBis-Tris Gels, Invitrogen, Life Technologies, or Bio-
Rad) for the detection of LMOD3, followed by transfer of proteins onto 
nitrocellulose membrane for 1 hour in Tris-Glycine buffer containing 
0.075% SDS. Membranes were blocked in 5% skim milk (diluted in 
PBS 0.1% Tween 20) for 1 hour, followed by incubation in primary Ab 
for 2 hours at room temperature or for 16 hours at 4°C. Unbound pri-
mary Ab was removed by washing for 25 minutes in PBS 0.1% Tween 
20, followed by 15 minutes of blocking. Secondary HRP Ab (1:2,000 in 
block for 1 hour at room temperature) and ECL Chemiluminescence 
Detection System (GE Healthcare Life Science) were used for detec-
tion. In some cases membranes were stripped of bound Ab by washing 
in 62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 0.1 M β-mercaptoethanol 
for 30 minutes. Stripping buffer was removed by washing 5 times for 
1 minute in large volumes of PBS 0.1% Tween 20, and membranes 
were reprobed. Membranes were stained for total proteins with 
Coomassie Blue Brilliant (Sigma-Aldrich).
For Western blot studies of zebrafish samples, protein extracts 
were established from flash frozen fish embryo samples (3 days after 
fertilization) using a RIPA protein extraction buffer with complete 
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(Pierce) and by measuring their difference spectra in 6 M guanidine- 
HCl as previously described (30).
CD measurements. CD measurements were done using an Aviv 
model 420SF spectrometer in 1-mm cuvettes. The peptide concen-
trations were 10 μM in 100 mM NaCl, 10 mM Na-Phosphate buffer, 
pH 7.0. Change of helical content during temperature denatura-
tion was monitored at 222 nm. The dissociation constants, KD, of 
the LMOD/TM peptide complexes were determined as previously 
described (35). Dissociation constants were statistically compared 
using a 2-tailed t test, and values are shown as mean ± SD.
Single-fiber mechanics and staining of stretched myofiber bundles
Contractile properties were measured in myofiber bundles isolated 
from frozen muscle biopsies using methods described previously (16, 
36). Force response to saturating Ca2+ concentrations (pCa 4.5) was 
measured at different SLs 2.0, 2.2, 2.5, 2.8, 3.2, and 3.5 μm. Forces were 
normalized to cross-sectional area measured at 2.5 μm SL. For force/
SL curves, forces at various SLs were normalized to the highest force 
obtained. At least 5 bundles were measured per biopsy. MHC isoform 
content of bundles was determined by SDS-PAGE electrophoresis 
as described previously (16). Force/SL curves were statistically com-
pared with pooled control values using repeated-measures ANOVA. 
Values are shown as mean ± SD.
For confocal imaging of phalloidin studies performed on myofi-
ber bundles dissected from frozen LMOD3-NM patient biopsies and 
age-matched controls, small aluminum clips were glued to a glass 
slide. Fiber bundles from frozen biopsies were stretched and fixed 
between the aluminum clips in relaxing buffer with protease inhibi-
tors. Stretched bundles were then fixed using 3% paraformaldehyde 
in PBS for 20 minutes at 4°C, followed by washes in PBS (5 buffer 
changes, last wash overnight at 4°C). Bundles were blocked for 1 hour 
in 1% BSA in PBS and labeled with 1 unit phalloidin conjugated to 
Alexa Fluor 488 for 48 hours. Unbound phalloidin was rinsed off, and 
bundles were mounted in Vectashield (Vector Laboratories) with #0 
coverslips. Staining was analyzed by confocal microscopy, and thin fil-
ament length was measured using ImageJ (version 1.44, from Wayne 
Rasband, National Institutes of Health, Bethesda, Maryland, USA; 
http://rsb.info.nih.gov/ij/index.html).
Statistics 
Statistical analysis was performed as specified in figure legends and 
in the appropriate methods section. A P value of less than 0.05 was 
considered significant.
Study approval
Ethical approval for this research was obtained from the Human 
Research Ethics Committees of the Children’s Hospital at Westmead 
(10/CHW/45), the University of Western Australia, Bicêtre Univer-
sity Hospital (NI10054), the Children’s Hospital of the University 
of Helsinki, the Japanese National Center of Neurology and Psychi-
atry, and the Boston Children’s Hospital Institutional Review Board 
(03-08-128R). Written informed consent was obtained for genetic 
testing of participants, biobanking of patient muscle and DNA, and 
publishing of patient photographs. Mouse muscle analyses were per-
formed using an Animal Care and Ethics Committee protocol locally 
approved at the Children’s Hospital at Westmead. Zebrafish were 
housed and bred under the University of Michigan’s University Com-
Assessment of muscle function. Spontaneous coiling was assessed in 
zebrafish 24 hours after fertilization by counting the number of coiling 
events in a 15-second epoch. Groups of 20 live embryos were videoed 
together using a Nikon Macroscope, and then coiling was measured 
via examination of video data.
Touch-evoked escape response data was generated as previ-
ously described (27).
Contractile properties of whole zebrafish trunk muscles were 
measured at 3 days after fertilization as previously described (25, 28). 
The width of the trunk, as viewed from ventral and lateral aspects, was 
measured, and cross-sectional area was estimated from these mea-
surements assuming an ellipse (28). Values are shown as mean ± SD.
Actin nucleation/polymerization assay
Expression of recombinant leiomodin proteins. Full-length LMOD2 and 
LMOD3 were expressed and purified as previously described (10). Fol-
lowing purification, proteins were exchanged into 20 mM Tris-HCl, 
pH 7.4, for biochemical assays.
Actin purification. Chicken pectoral skeletal muscle G-actin was 
purified from acetone powder as previously described (29) and was 
kept on ice in 2 mM Tris-HCl, pH 8, 0.5 mM DTT, 0.2 mM ATP, 0.2 
mM CaCl2, 0.01% NaN3 to use fresh in fluorescence experiments. 
Actin concentration was determined by measuring difference spec-
tra in 6 M guanidine-HCl between pH 12.5 and 7.0, using extinction 
coefficients of 2,357 per tyrosine and 830 per tryptophan as previously 
described (30). G-actin labeled with pyrene-iodoacetamide was pre-
pared as previously described (31). Labeling ratios (~90 %) were calcu-
lated as previously described (32), and pyrene actin was stored in liq-
uid nitrogen. Before experiments, pyrene actin was defrosted at 37°C 
and centrifuged at 386,000 g (TLA-100, Beckman) for 30 minutes at 
4 °C to remove aggregates. The same solution of G-actin was used for 
all experiments to decrease the measurement error.
Fluorescence measurements. Actin polymerization was monitored 
by the increase in fluorescence using a Photon Technology Interna-
tional spectrofluorometer, Model QM-40 (QuantaMaster-40) (excita-
tion 366 nm and emission 387 nm, with a 2-nm slit). To measure actin 
nucleation by LMOD, 1.1 μM G-actin (10 % pyrenyl-actin) was mixed 
with 2, 5, 20, 50, and 100 nM LMOD, and the reaction was initiated 
by addition of 20x polymerization buffer to final concentrations of 
10 mM imidazole, pH 7.0, containing 100 mM KCl, 2 mM MgCl2, and 
1 mM EGTA. Spontaneous actin nucleation in the absence of LMOD 
was measured as a control.
TM binding
Peptides. Peptides for CD measurements were synthesized by the 
Tufts University Core Facility. The TM peptide is a designed acety-
lated chimeric peptide that consists of 14 N-terminal residues of long 
α-TM encoded by exon 1a, which contains the TMOD-binding site, 
and the 18 C-terminal residues of the GCN4 leucine zipper domain, 
which help to stabilize the coiled-coil structure (33, 34). Note that the 
corresponding N-terminal sequence of long muscle β-TM encoded 
by exon 1a is identical to the α-TM sequence. Leiomodin fragments 
(amino acids 5–42 for mouse LMOD2 and amino acids 6–44 for mouse 
LMOD3) were designed based on alignment with the first TM-binding 
site of TMOD1. The synthetic peptides were purified and analyzed on 
HPLC, and their quality was confirmed using mass spectrometry. Con-
centrations of peptides were determined by a BCA Protein Assay Kit 
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